Cullen/Frost Bankers, Inc. Spero Therapeutics, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.83 Billion
- Q2 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 2,000 shares of SPRO stock, worth $4,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000
Previous 2,000
-0.0%
Holding current value
$4,300
Previous $1,000
400.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding SPRO
# of Institutions
50Shares Held
10.5MCall Options Held
0Put Options Held
186K-
Vanguard Group Inc Valley Forge, PA1.95MShares$4.19 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX1.62MShares$3.47 Million0.86% of portfolio
-
Atlas Venture Associates Ix, LLC Boston, MA1.35MShares$2.91 Million14.54% of portfolio
-
Alphabet Inc. Mountain View, CA890KShares$1.91 Million0.17% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny832KShares$1.79 Million0.0% of portfolio
About Spero Therapeutics, Inc.
- Ticker SPRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,067,500
- Market Cap $75.4M
- Description
- Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...